Total Payments
$748.40
2023 Payments
$105.73
Companies
19
Transactions
38
Medicare Patients
9,327
Medicare Billing
$616,203
Payment Breakdown by Category
Food & Beverage$718.40 (96.0%)
Education$30.00 (4.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $718.40 | 36 | 96.0% |
| Education | $30.00 | 2 | 4.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $96.93 | 5 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $91.34 | 3 | $0 (2022) |
| Incyte Corporation | $70.98 | 3 | $0 (2023) |
| PFIZER INC. | $56.64 | 3 | $0 (2019) |
| GENZYME CORPORATION | $56.54 | 2 | $0 (2017) |
| Janssen Scientific Affairs, LLC | $49.61 | 1 | $0 (2019) |
| UCB, Inc. | $45.99 | 2 | $0 (2022) |
| Galderma Laboratories, L.P. | $42.51 | 3 | $0 (2020) |
| Celgene Corporation | $32.77 | 3 | $0 (2018) |
| Sun Pharmaceutical Industries Inc. | $30.35 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $105.73 | 6 | ABBVIE INC. ($42.00) |
| 2022 | $125.71 | 5 | Regeneron Healthcare Solutions, Inc. ($34.35) |
| 2021 | $41.30 | 2 | Incyte Corporation ($23.62) |
| 2020 | $30.10 | 2 | Sun Pharmaceutical Industries Inc. ($16.20) |
| 2019 | $154.04 | 6 | Janssen Scientific Affairs, LLC ($49.61) |
| 2018 | $80.12 | 5 | PFIZER INC. ($21.61) |
| 2017 | $211.40 | 12 | GENZYME CORPORATION ($56.54) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/22/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $21.62 | General |
| Category: Dermatology | ||||||
| 06/13/2023 | Sun Pharmaceutical Industries Inc. | Winlevi (Drug) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: Dermatology | ||||||
| 06/01/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: IMMUNOLOGY | ||||||
| 03/15/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.16 | General |
| Category: IMMUNOLOGY | ||||||
| 02/21/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $13.54 | General |
| Category: Immunology | ||||||
| 01/18/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: DERMATOLOGY | ||||||
| 12/13/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $34.35 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/22/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $25.74 | General |
| Category: Dermatology | ||||||
| 06/15/2022 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Immunology | ||||||
| 03/02/2022 | Almirall LLC | Seysara (Drug) | Food and Beverage | Cash or cash equivalent | $18.13 | General |
| Category: Dermatology | ||||||
| 02/02/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $25.25 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2021 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $23.62 | General |
| Category: Dermatology | ||||||
| 11/09/2021 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Inflammation | ||||||
| 01/28/2020 | Galderma Laboratories, L.P. | EPIDUO FORTE (Drug), AKLIEF | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: ACNE | ||||||
| 01/07/2020 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | Cash or cash equivalent | $16.20 | General |
| Category: Dermatology | ||||||
| 09/21/2019 | Janssen Scientific Affairs, LLC | Tremfya (Drug) | Food and Beverage | In-kind items and services | $49.61 | General |
| Category: Immunology | ||||||
| 09/19/2019 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: Immunology | ||||||
| 05/21/2019 | Helsinn Therapeutics (U.S.), Inc. | VALCHLOR (Drug) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: ONCOLOGY | ||||||
| 05/01/2019 | AbbVie, Inc. | Humira (Biological), Skyrizi | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: Immunology | ||||||
| 03/27/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: DERMATOLOGY | ||||||
| 03/20/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.74 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/18/2018 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: DERMATOLOGY | ||||||
| 09/11/2018 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: Immunology | ||||||
| 06/26/2018 | Janssen Biotech, Inc. | REMICADE (Biological), STELARA, SIMPONI | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Immunology | ||||||
| 04/17/2018 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $11.08 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,272 | 1,991 | $172,455 | $55,142 |
| 2022 | 12 | 2,495 | 4,890 | $441,445 | $175,886 |
| 2021 | 11 | 2,813 | 5,774 | $511,605 | $210,161 |
| 2020 | 11 | 2,747 | 5,023 | $482,975 | $175,013 |
Total Patients
9,327
Total Services
17,678
Medicare Billing
$616,203
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 514 | 537 | $74,297 | $26,518 | 35.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 280 | 307 | $36,005 | $9,076 | 25.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 109 | 116 | $21,728 | $6,166 | 28.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 48 | 52 | $8,264 | $3,208 | 38.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 185 | 830 | $11,416 | $3,114 | 27.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 73 | 81 | $7,218 | $2,411 | 33.4% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 19 | 20 | $4,955 | $2,134 | 43.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 30 | $6,225 | $1,925 | 30.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 17 | 18 | $2,347 | $590.32 | 25.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 984 | 1,277 | $159,625 | $78,570 | 49.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 470 | 678 | $84,750 | $25,141 | 29.7% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 286 | 350 | $61,250 | $23,213 | 37.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 115 | 127 | $19,850 | $9,632 | 48.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 335 | 2,047 | $40,940 | $9,619 | 23.5% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2022 | 37 | 42 | $14,700 | $7,425 | 50.5% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 35 | 58 | $14,500 | $6,666 | 46.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 41 | 62 | $10,850 | $5,289 | 48.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 97 | 117 | $11,700 | $4,330 | 37.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 70 | 105 | $18,375 | $3,721 | 20.3% |
| 11401 | Removal of noncancer skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2022 | 11 | 13 | $2,665 | $1,344 | 50.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 14 | 14 | $2,240 | $936.89 | 41.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 970 | 1,261 | $157,625 | $80,904 | 51.3% |
| 17000 | Destruction of skin growth | Office | 2021 | 537 | 873 | $109,125 | $33,307 | 30.5% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 319 | 403 | $70,525 | $27,931 | 39.6% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 173 | 246 | $36,900 | $19,008 | 51.5% |
About Dr. Susan Kucirka, MD
Dr. Susan Kucirka, MD is a Dermatology healthcare provider based in Schnecksville, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245209063.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Susan Kucirka, MD has received a total of $748.40 in payments from pharmaceutical and medical device companies, with $105.73 received in 2023. These payments were reported across 38 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($718.40).
As a Medicare-enrolled provider, Kucirka has provided services to 9,327 Medicare beneficiaries, totaling 17,678 services with total Medicare billing of $616,203. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Schnecksville, PA
- Active Since 03/15/2006
- Last Updated 07/29/2010
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1245209063
Products in Payments
- OPZELURA (Drug) $70.98
- SKYRIZI (Biological) $67.25
- DUPIXENT (Biological) $67.09
- Tremfya (Drug) $63.32
- EUCRISA (Drug) $56.64
- DUPIXENT (Drug) $56.54
- Cimzia (Drug) $45.99
- KERYDIN (Drug) $30.00
- Humira (Biological) $29.68
- Otezla (Drug) $28.76
- EPIDUO FORTE (Drug) $26.29
- DUPIXENT DUPILUMAB INJECTION (Biological) $24.25
- TALTZ (Drug) $19.28
- DORYX (Drug) $18.72
- Seysara (Drug) $18.13
- ORACEA (Drug) $16.22
- ILUMYA (Biological) $16.20
- REMICADE (Biological) $15.25
- VTAMA (Drug) $14.42
- Winlevi (Drug) $14.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.